Looksmaxxing, but with receipts
Is it legal? Has anyone actually tested it? What went wrong for the people who tried? We check the regulator, the trials and the lab results, and date every number. No dosing, no sourcing lists, no sales pitch.
Five checks on every compound, no exceptions
Each line is read from the source, dated, and recomputed in the open. The figures come from the guides that own them and change when the sources do.
- 01
Regulatory status
Is it legal? We read the regulator's own page and print its date.
22 Apr 2026FDA page date, BPC-157 - 02
Human trials
Has anyone tested it on humans? Counted on PubMed and ClinicalTrials.gov, query linked.
0BPC-157 trial-typed papers - 03
Harms
What went wrong. Case reports and regulator statements, not forum lore.
11melanotan II case reports - 04
Quality tests
Do the tests hold up? Results, each labelled by who ran them.
91 of 197failed on one tester's page - 05
Dated
Receipts expire. Every figure shows when we read it and when we check again.
30 Novnext review
How much copium is your topic running on?
Hype against randomized trials, computed for fifteen topics, with a verdict you can copy and post. It rates topics, never people.
Check the Copium Meter308Kyearly wiki views
0randomized-trial papers
BPC-157: Pure copium
5 guides across 2 sections so far
Compound checks and the evidence ladder, each guide dated and sourced.
BPC-157: status, trials and harms
FDA lists it as nominated and withdrawn, PubMed has no trial-tagged papers, and neither an advisory vote nor a new HHS draft policy is an approval.
Read the receipttrial-tagged papers on PubMed (semaglutide has 344, for scale only)
MK-677 (ibutamoren): status, trials and harms
The deepest trial record of any unapproved compound in the table, and FDA still lists it in Category 2 for a heart-failure risk.
How FDA's peptide categories work
Category 1, 2, 3 and "withdrawn", which peptides sit where, and why a vote or a label is not a ruling.
HHS peptide enforcement notice: what it says
A draft, non-binding HHS policy on compounding certain peptides: what it is not, who it covers, and when comments close.